New imaging probe aims to spot kidney cancer earlier

NCT ID NCT07590310

Recruiting now Diagnosis Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new radioactive imaging agent called 68Ga/18F-CAIX-LT-BCH to see if it can better detect clear cell renal cell carcinoma, a common type of kidney cancer. The study involves 3 participants who will receive the agent and undergo a PET/CT scan. The goal is to improve early, non-invasive diagnosis by targeting a protein called CAIX, which is highly expressed in these tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga/18F-CAIX-LT-BCH (a radioactive imaging agent)
What this could lead to: If successful, this could provide a more accurate, non-invasive way to detect clear cell kidney cancer early, potentially improving patient outcomes.
What could go wrong: This is a very early, small trial with only 3 participants, so results may not apply broadly. The imaging agent may not perform as well in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer nonpapillary renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY CANCERS

Contacts and locations

Locations

Peking University Cancer Hospital
RECRUITING

Beijing, Haidian, 10000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.